EUS-guided radiofrequency ablation in the pancreas

Česká verzia

Authors: J. Jarošová; P. Mačinga; A. Hujová; T. Hucl
Authors place of work: Klinika hepatogastroenterologie, Institut klinické a experimentální medicíny, Praha
Published in the journal: Gastroent Hepatol 2024; 78(5): 388-394
Category:
doi: https://doi.org/10.48095/ccgh2024388

Summary

Incident cystic lesions of the pancreas are diagnosed with increased frequency due to increased use of CT or MR imaging in asymptomatic patients who undergo imaging for other reasons. Certain lesions such as neuroendocrine tumors, mucinous cystadenomas, and intraductal papillary mucinous neoplasia are at significant risk of the presence or development of malignancy. Endosonographically guided radiofrequency ablation allows selective ablation of the pancreatic lesion with minimal damage to surrounding tissue and could be an alternative treatment modality for patients who do not want or cannot undergo surgery or do not wish to have a long-term follow-up. Based on the available pilot studies, EUS-RFA appears to be a promising technically feasible method for the treatment of pancreatic neoplasia, which has demonstrated high technical and acceptable clinical success rates with low morbidity. This communication offers a clear summary of the use of EUS-RFA in solid and cystic pancreatic neoplasia concluding with two case reports of patients. In both cases, endoscopic treatment was technically feasible and no periprocedural or postprocedural complications occurred.

Keywords:

radiofrequency ablation – pancreas – neuroendocrine tumour – pancreatic cystic lesion

Zdroje

1. Keter D, Melzer E. Endoscopic ultrasound in clinical practice. Acta Gastroenterol Latinoam 2008; 38 (2): 146–151.

2. Dumonceau JM, Deprez PH, Jenssen C et al. Indications, results, and clinical impact of endoscopic ultrasound (EUS) -guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline – Updated January 2017. Endoscopy 2017; 49 (7): 695–714. doi: 10.1055/s-0043-109021.

3. Laffan TA, Horton KM, Klein AP et al. Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol 2008; 191 (3): 802–807. doi: 10.2214/AJR.07.3340.

4. Kromrey ML, Bülow R, Hübner J et al. Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a population-based study. Gut 2018; 67 (1): 138–145. doi: 10.1136/gutjnl-2016-313127.

5. Fernández-del Castillo C, Targarona J, Thayer SP et al. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 2003; 138 (4): 427–434. doi: 10.1001/archsurg.138.4.427.

6. Grützmann R, Niedergethmann M, Pilarsky C et al. Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist 2010; 15 (12): 1294–1309. doi: 10.1634/theoncologist.2010-0151.

7. Choi SH, Park SH, Kim KW et al. Progression of Unresected Intraductal Papillary Mucinous Neoplasms of the Pancreas to Cancer: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2017; 15 (10): 1509–1520.e4. doi: 10.1016/j.cgh.2017.03.020.

8. Lawrence B, Gustafsson BI, Chan A et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011; 40 (1): 1–18. doi: 10.1016/ j.ecl.2010.12.005.

9. Gomez-Rivera F, Stewart AE, Arnoletti JP et al. Surgical treatment of pancreatic endocrine neoplasms. Am J Surg 2007; 193 (4): 460–465. doi: 10.1016/j.amjsurg.2006.10.016.

10. Tanaka M, Heckler M, Mihaljevic AL et al. Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors. Ann Surg Oncol 2021; 28 (3): 1614–1624. doi: 10.1245/s10434-020-08850-7.

11. Heidsma CM, Engelsman AF, van Dieren S et al. Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA). Br J Surg 2021; 108 (8): 888–891. doi: 10.1093/bjs/znab088.

12. Goldberg SN, Gazelle GS. Radiofrequency tissue ablation: physical principles and techniques for increasing coagulation necrosis. Hepatogastroenterology 2001; 48 (38): 359–367.

13. Goldberg SN. Radiofrequency tumor ablation: principles and techniques. Eur J Ultrasound 2001; 13 (2): 129–147. doi: 10.1016/s0929- 8266 (01) 00126-4.

14. Gazelle GS, Goldberg SN, Solbiati L et al. Tumor ablation with radio-frequency energy. Radiology 2000; 217 (3): 633–646. doi: 10.1148/ radiology.217.3.r00dc26633.

15. Van den Bijgaart RJ, Eikelenboom DC, Hoogenboom M et al. Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. Cancer Immunol Immunother 2017; 66 (2): 247–258. doi: 10.1007/s00262-016-1891-9.

16. Pai M, Habib N, Senturk H et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg 2015; 7 (4): 52–59. doi: 10.4240/wjgs.v7.i4.52.

17. Crinò SF, D‘Onofrio M, Bernardoni L et al. EUS-guided Radiofrequency Ablation (EUS-RFA) of Solid Pancreatic Neoplasm Using an 18-gauge Needle Electrode: Feasibility, Safety, and Technical Success. J Gastrointestin Liver Dis 2018; 27 (1): 67–72. doi: 10.15403/jgld.2014.1121. 271.eus.

18. Lakhtakia S, Seo DW. Endoscopic ultrasonography-guided tumor ablation. Dig Endosc 2017; 29 (4): 486–494. doi: 10.1111/den. 12833.

19. Lakhtakia S, Ramchandani M, Galasso D et al. EUS-guided radiofrequency ablation for management of pancreatic insulinoma by using a novel needle electrode (with videos). Gastrointest Endosc 2016; 83 (1): 234–239. doi: 10.1016/j.gie.2015.08.085.

20. Song TJ, Seo DW, Lakhtakia S et al. Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer. Gastrointest Endosc 2016; 83 (2): 440–443. doi: 10.1016/j.gie.2015.08.048.

21. Armellini E, Crinò SF, Ballarè M et al. Endoscopic ultrasound-guided radiofrequency ablation of a pancreatic neuroendocrine tumor. Endoscopy 2015; 47 (Suppl 1 UCTN): E600–E601. doi: 10.1055/s-0034-1393677.

22. Barthet M, Giovannini M, Lesavre N et al. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study. Endoscopy 2019; 51 (9): 836–842. doi: 10.1055/a-0824-7067.

23. Barthet M, Giovannini M, Gasmi M et al. Long-term outcome after EUS-guided radiofrequency ablation: Prospective results in pancreatic neuroendocrine tumors and pancreatic cystic neoplasms. Endosc Int Open 2021; 9 (8): E1178–E1185. doi: 10.1055/a-1479-2199.

24. Rossi S, Viera FT, Ghittoni G et al. Radiofrequency ablation of pancreatic neuroendocrine tumors: a pilot study of feasibility, efficacy, and safety. Pancreas 2014; 43 (6): 938–945. doi: 10.1097/MPA.0000000000000133.

25. Napoléon B, Lisotti A, Caillol F et al. Risk factors for EUS-guided radiofrequency ablation adverse events in patients with pancreatic neoplasms: a large national French study (RAFPAN study). Gastrointest Endosc 2023; 98 (3): 392.e1–399.e1. doi: 10.1016/j.gie.2023. 04.003.

26. Borrelli de Andreis F, Boškoski I, Mascagni P et al. Safety and efficacy of endoscopic ultrasound-guided radiofrequency ablation for pancreatic insulinoma: A single-center experience. Pancreatology 2023; 23 (5): 543–549. doi: 10.1016/j.pan.2023.05.004.

27. Kadri S, Malde D P335 First UK experience of EUS guided RFA for solid pancreatic tumour. Gut 2023; 72 (Suppl 2): A227.1–A227.1. Doi: 10.1136/gutjnl-2023-BSG.399.

28. Okasha H, Altonbary A, Ragab K, et al P156 A prospective multicenter study of the endoscopic ultrasound-guided radiofrequency (EUS-RFA) vs ethanol ablation (EUS-EA) for pancreatic neuroendocrine tumors and Adenocarcinoma, Gut 2024; 73: A146–A147.

29. Crinò SF, Napoleon B, Facciorusso A et al. Endoscopic Ultrasound-guided Radiofrequency Ablation Versus Surgical Resection for Treatment of Pancreatic Insulinoma. Clin Gastroenterol Hepatol 2023; 21 (11): 2834.e2–2843.e2. doi: 10.1016/j.cgh.2023.02.022.

30. Ofosu A, Ramai D, Morgan A et al. EUS-guided radiofrequency ablation of solid pancreatic lesions: An updated review. Endosc Ultrasound 2024; 13 (1): 1–5. doi: 10.1097/eus. 0000000000000036.

31. Prete AM, Gonda TA. Endoscopic Ultrasound-Guided Local Ablative Therapies for the Treatment of Pancreatic Neuroendocrine Tumors and Cystic Lesions: A Review of the Current Literature. J Clin Med 2023; 12 (9): 3325. doi: 10.3390/jcm12093325.

32. Girelli R, Frigerio I, Salvia R et al. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg 2010; 97 (2): 220–225. doi: 10.1002/bjs. 6800.

33. Melita G, Pallio S, Tortora A et al. Diagnostic and Interventional Role of Endoscopic Ultrasonography for the Management of Pancreatic Neuroendocrine Neoplasms. J Clin Med 2021; 10 (12): 2638. doi: 10.3390/jcm101 22638.

34. Choi JH, Seo DW, Song TJ et al. Endoscopic ultrasound-guided radiofrequency ablation for management of benign solid pancreatic tumors. Endoscopy 2018; 50 (11): 1099–1104. doi: 10.1055/a-0583-8387.

35. De Nucci G, Imperatore N, Mandelli ED et al. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a case series. Endosc Int Open 2020; 8 (12): E1754–E1758. doi: 10.1055/a-1261-9359.

36. Oleinikov K, Dancour A, Epshtein J et al. Endoscopic Ultrasound-Guided Radiofrequency Ablation: A New Therapeutic Approach for Pancreatic Neuroendocrine Tumors. J Clin Endocrinol Metab 2019; 104 (7): 2637–2647. doi: 10.1210/jc.2019-00282.

37. Furnica RM, Deprez P, Maiter D et al. Endoscopic ultrasound-guided radiofrequency ablation: An effective and safe alternative for the treatment of benign insulinoma. Ann Endocrinol (Paris) 2020; 81 (6): 567–571. doi: 10.1016/ j.ando.2020.11.009.

38. Marx M, Trosic-Ivanisevic T, Caillol F et al. EUS-guided radiofrequency ablation for pancreatic insulinoma: experience in 2 tertiary centers. Gastrointest Endosc 2022; 95 (6): 1256–1263. doi: 10.1016/j.gie.2021.11.045.

39. Marx M, Godat S, Caillol F et al. Management of non-functional pancreatic neuroendocrine tumors by endoscopic ultrasound-guided radiofrequency ablation: Retrospective study in two tertiary centers. Dig Endosc 2022; 34 (6): 1207–1213. doi: 10.1111/den.14224.

ORCID autorů

J. Jarošová 0000-0002-0275-4282,

P. Mačinga 0000-0003-3699-6914,

A. Hujová 0000-0002-1282-095X,

T. Hucl 0000-0002-5648-4011.

Doručeno/Submitted: 7. 10. 2024

Přijato/Accepted: 17. 10. 2024

Korespondenční autor

prof. MUDr. Tomáš Hucl, Ph.D.

Klinika hepatogastroenterologie

Institut klinické a experimentální medicíny

Vídeňská 1958/9